Virpax Pharmaceuticals Inc Stock Analysis:
Based on the Virpax Pharmaceuticals Inc stock forecasts from 2 analysts, the average analyst target price for Virpax Pharmaceuticals Inc is USD 4.00 over the next 12 months. Virpax Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Virpax Pharmaceuticals Inc is Very Bearish, which is based on 0 positive signals and 3 negative signals. At the last closing, Virpax Pharmaceuticals Inc’s stock price was USD 1.63. Virpax Pharmaceuticals Inc’s stock price has changed by -8.43% over the past week, +13.99% over the past month and -68.65% over the last year.
Virpax Pharmaceuticals specialises in developing unique and proprietary drug-delivery systems across a range of indications for pain and CNS disorders. The company’s changing drug-delivery platforms and their focused drug-releasing capabilities were created to maximise the efficacy of the pipelines for CNS disorders and non-addictive pain treatment.
What we like:
There is no fundamental attribute that we can detect on the stock that would warrant a positive outlook. The stock is a pure speculative play!
What we don’t like:
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.